Section 164.241 - Provision of Services(A)Assessment. Pursuant to 105 CMR 164.072(B), the Licensed or Approved Provider may initiate patient treatment prior to completion of the assessment required by 105 CMR 164.072 upon obtaining sufficient information to initiate treatment for the acute problem at the time of presentation and that the assessment is subsequently completed in a reasonable timeframe, provided that a Qualified Healthcare Professional must see such a patient prior to initiating an FDA-approved medication for treatment of addiction. In addition to the assessment required by 105 CMR 164.072 and prior to admission, the Licensed or Approved Provider shall conduct a screening to determine acupuncture is not contraindicated. The screening shall include, at a minimum: (1) patient's history of seizures, delirium tremens or other life-threatening withdrawal symptoms, which constitute a risk to the patient's health or well-being;(2) neurological evidence of an appropriate level of consciousness; and(B)Admission. Upon conclusion of the assessment required by 105 CMR 164.072, the Licensed or Approved Provider shall only admit those patients with a substance use disorder who are not in a current or potential state of withdrawal that constitutes a risk to the patient's health and well-being, which requires medical attention or medical monitoring beyond the scope of the Licensed or Approved Provider's services.(C)Treatment. The Licensed or Approved Provider shall provide intensive acupuncture administration of six treatments per week for withdrawal purposes, followed by less intensive treatment of two to three times per week for relapse prevention.Adopted by Mass Register Issue 1482, eff. 11/11/2022.